➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
Colorcon
Moodys
AstraZeneca

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Lidocaine Hydrochloride 5% And Dextrose 7.5% patents expire, and when can generic versions of Lidocaine Hydrochloride 5% And Dextrose 7.5% launch?

Lidocaine Hydrochloride 5% And Dextrose 7.5% is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Lidocaine Hydrochloride 5% And Dextrose 7.5%

A generic version of LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18th, 1982.

  Start Trial

Summary for LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%
Drug patent expirations by year for LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%
Recent Clinical Trials for LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St. Joseph's Healthcare HamiltonPhase 2
Pain Management Institute Bethesda-Washington-MarylandN/A
Scilex Pharmaceuticals, Inc.N/A

See all LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% clinical trials

Pharmacology for LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% lidocaine hydrochloride INJECTABLE;SPINAL 083914-001 Approved Prior to Jan 1, 1982 RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Medtronic
Merck
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.